Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Chemoradiotherapy
100%
Response to Therapy
100%
Prognostic Biomarker
100%
Selection Criteria
100%
HPV-related Oropharyngeal Cancer
100%
Narrative Review
100%
Human Papillomavirus-related Oropharyngeal Cancer
100%
Early Tumor Response
100%
Biomarkers Tumor
100%
Standard of Care
60%
Cancer Patients
40%
Response-adapted
40%
Good Prognosis
40%
Low-risk Human Papillomavirus
40%
Treatment De-escalation
40%
Early Response
20%
Hypoxia
20%
Multicenter Randomized Trial
20%
Selection Strategy
20%
Single-arm Study
20%
Chemoradiation
20%
Induction Chemotherapy
20%
Reduced Intensity
20%
Nonrandomized Studies
20%
Clinical Factors
20%
Cure Rate
20%
Multiple Candidates
20%
Lack of Information
20%
Clinical Aspects
20%
Methodological Limitations
20%
Risk of Bias
20%
Methodological Aspects
20%
Prognostic Potential
20%
Molecular Factors
20%
Reduced Toxicity
20%
Narrative Literature Review
20%
Internal Validation
20%
Comparison with a Standard
20%
External Validation
20%
Clinical Utilization
20%
Narrative Reporting
20%
Review Strategy
20%
DNA Kinetics
20%
Response Indicators
20%
Imaging Factors
20%
Clinical Outcomes
20%
Sufficient Follow-up
20%
Histopathological Factors
20%
Small Cohorts
20%
Metabolic Imaging
20%
Loss-to-follow-up
20%
Historical Result
20%
Histopathological Imaging
20%
Circulating HPV DNA
20%
Nursing and Health Professions
Oropharynx Cancer
100%
Biological Marker
100%
Neoplasm
100%
Chemoradiotherapy
100%
Oropharynx Carcinoma
100%
Health Care Quality
50%
Imaging
33%
Literature Review
16%
Clinical Outcome
16%
Induction Chemotherapy
16%
Preclinical Study
16%
Hypoxia
16%
Medicine and Dentistry
Biological Marker
100%
Neoplasm
100%
Chemoradiotherapy
100%
Oropharynx Carcinoma
100%
Wart Virus
83%
Hypoxia
16%
Arm
16%
Induction Chemotherapy
16%
Cohort Studies
16%
Biochemistry, Genetics and Molecular Biology
Wart Virus
100%
Prognostic Biomarker
100%
Cohort Study
20%
Preclinical Study
20%
Immunology and Microbiology
Wart Virus
100%
Prognostic Biomarker
100%
Arm
20%
Preclinical Study
20%